Firms

Casdin Capital
Signal profile (Casdin Capital) Casdin Capital cb Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement. SHOW MORE Founded: 2012
- Founded
- 2012
- Type
- Venture capital
Funds0
No funds on record yet.
Team
No team members on record yet.
Co-investing
ARCH Venture Partners
City Therapeutics$99M · 2026-06-08
Remix Therapeutics$60M · 2024-01-03nChroma$75M · 2024
Maze Therapeutics$115M · 2024
Orbital Therapeutics$270M · 2023-04-26
Chroma Medicine$135M · 2023-03-01
ONI$75M · 2022-01-20
Sonoma Biotherapeutics$265M · 2021-08-04
Prime Medicine, Inc.$200M · 2021-07-13
Vividion Therapeutics$82M · 2019-04-30
908 Devices$— · 2019-04-29
Codiak Biosciences$76M · 2017-11-29
Prime Medicine, Inc.$— · Unknown date
Vividion$82M · Unknown date
Rome$72M · Unknown date
Alexandria Venture Investments
Remix Therapeutics$60M · 2024-01-03
Neurogene$95M · 2023-12-18
Orbital Therapeutics$270M · 2023-04-26
Neurogene$115M · 2020-12-16
Vividion Therapeutics$82M · 2019-04-30
Codiak Biosciences$76M · 2017-11-29
Vividion$82M · Unknown date
Rome$72M · Unknown date
S32
Octave Bioscience$35M · 2025-09-04
Character Biosciences$93M · 2025-03-25
Octave Bioscience$30M · 2023-07-26
ONI$75M · 2022-01-20
Formation Bio$156M · 2021-09-30
C2i Genomics$100M · 2021-04-15
Octave Bioscience$32M · 2020-12-17
Vineti$35M · 2020-02-05
Andreessen Horowitz
Maze Therapeutics$115M · 2024
Thyme Care$60M · 2023-08-22
Orbital Therapeutics$270M · 2023-04-26
Thyme Care$22M · 2021-10-05
EQRx$1.8B · 2021
Nautilus Biotechnology$76M · 2020
Cormorant Asset ManagementnChroma$75M · 2024
Neurogene$95M · 2023-12-18
Chroma Medicine$135M · 2023-03-01
Prime Medicine, Inc.$200M · 2021-07-13
Neurogene$115M · 2020-12-16
Prime Medicine, Inc.$— · Unknown date
Bain CapitalAmunix Pharmaceuticals$117M · 2021-03-04
Amunix$117M · 2021-03-04
EQRx$1.8B · 2021
Nautilus Biotechnology$76M · 2020
Franklin Templeton
Amunix Pharmaceuticals$117M · 2021-03-04
Amunix$117M · 2021-03-04
EQRx$1.8B · 2021
Nautilus Biotechnology$76M · 2020
Mirae Asset
Sonoma Biotherapeutics$265M · 2021-08-04
Vividion Therapeutics$82M · 2019-04-30
Vividion$82M · Unknown date
Rome$72M · Unknown date
Northpond Ventures
Octave Bioscience$35M · 2025-09-04
Octave Bioscience$30M · 2023-07-26
Octave Bioscience$32M · 2020-12-17
908 Devices$— · 2019-04-29
Redmile Group
Neurogene$200M · 2024-11-04
Neurogene$95M · 2023-12-18
Prime Medicine, Inc.$200M · 2021-07-13
Neurogene$115M · 2020-12-16
Samsara BioCapital
Neurogene$200M · 2024-11-04
Neurogene$95M · 2023-12-18
Prime Medicine, Inc.$200M · 2021-07-13
Neurogene$115M · 2020-12-16
Section 32
ONI$75M · 2022-01-20
Formation Bio$156M · 2021-09-30
C2i Genomics$100M · 2021-04-15
Vineti$35M · 2020-02-05
Y Combinator
Nest Genomics$8M · 2023-01-10
Multiply Labs$20M · 2021
Asimov$175M · Unknown date
Rome$72M · Unknown date
Atlas Venture
Remix Therapeutics$60M · 2024-01-03nChroma$75M · 2024
Chroma Medicine$135M · 2023-03-01
F-Prime Capital
nChroma$75M · 2024
Prime Medicine, Inc.$200M · 2021-07-13
Prime Medicine, Inc.$— · Unknown date
General Catalyst
Beacon Biosignals$97M · 2025-11-13
Maze Therapeutics$115M · 2024
Beacon Biosignals$27M · 2021-11-08
GV
Beacon Biosignals$97M · 2025-11-13
Maze Therapeutics$115M · 2024
Prime Medicine, Inc.$200M · 2021-07-13
Moore Strategic Ventures
Maze Therapeutics$115M · 2024
Orbital Therapeutics$270M · 2023-04-26
Prime Medicine, Inc.$200M · 2021-07-13
The Blue Venture Fund
Octave Bioscience$35M · 2025-09-04
Octave Bioscience$30M · 2023-07-26
Octave Bioscience$32M · 2020-12-17
Viking Global Investors
City Therapeutics$99M · 2026-06-08Amunix Pharmaceuticals$117M · 2021-03-04
Amunix$117M · 2021-03-04
Vineeta Agarwala
Thyme Care$60M · 2023-08-22
Orbital Therapeutics$270M · 2023-04-26
Thyme Care$22M · 2021-10-05
AlleyCorp
Thyme Care$60M · 2023-08-22
Thyme Care$22M · 2021-10-05
Catalio Capital Management
Beacon Biosignals$97M · 2025-11-13
Character Biosciences$93M · 2025-03-25
Celgene
Vividion Therapeutics$82M · 2019-04-30
Vividion$82M · Unknown date
DCVC
Chroma Medicine$135M · 2023-03-01
Nest Genomics$8M · 2023-01-10
Echo Health Ventures
Octave Bioscience$30M · 2023-07-26
Octave Bioscience$32M · 2020-12-17
Fidelity Investments
City Therapeutics$99M · 2026-06-08
23andMe$250M · 2017-09-12
Foresite Capital
Thyme Care$60M · 2023-08-22
Cerevance$20M · 2020-07-21
Frist Cressey Ventures
Thyme Care$60M · 2023-08-22
Thyme Care$22M · 2021-10-05
Hemant Taneja
Beacon Biosignals$97M · 2025-11-13
Beacon Biosignals$27M · 2021-11-08
Hikma Ventures
Octave Bioscience$35M · 2025-09-04
Octave Bioscience$30M · 2023-07-26
Khosla Ventures
Volta Labs$20M · 2022-03-18
Earli$— · Unknown date
Lifeforce Capital
Sonoma Biotherapeutics$265M · 2021-08-04
Vineti$35M · 2020-02-05
Logos Capital
Beacon Biosignals$97M · 2025-11-13
Maze Therapeutics$115M · 2024
Longitude Capital
Amunix Pharmaceuticals$117M · 2021-03-04
Amunix$117M · 2021-03-04
Merck Global Health Innovation Fund
Octave Bioscience$35M · 2025-09-04
Octave Bioscience$30M · 2023-07-26
Mubadala Ventures
Vividion Therapeutics$82M · 2019-04-30
Vividion$82M · Unknown date
Newpath Partners
Orbital Therapeutics$270M · 2023-04-26
Prime Medicine, Inc.$200M · 2021-07-13
Osage University Partners
Chroma Medicine$135M · 2023-03-01
Sonoma Biotherapeutics$265M · 2021-08-04
Sanofi Ventures
Character Biosciences$93M · 2025-03-25
Rome$72M · Unknown date
Sequoia
Formation Bio$156M · 2021-09-30
23andMe$250M · 2017-09-12
Venrock
Amunix Pharmaceuticals$117M · 2021-03-04
Amunix$117M · 2021-03-04
Wellington Management
nChroma$75M · 2024
Chroma Medicine$135M · 2023-03-01
8VC
Sonoma Biotherapeutics$265M · 2021-08-04
Alaska Permanent Fund Corporation
Codiak Biosciences$76M · 2017-11-29
Altimeter Capital Management, LP
23andMe$250M · 2017-09-12
Alumni Ventures
Beacon Biosignals$97M · 2025-11-13
aMoon
Character Biosciences$93M · 2025-03-25
AN Venture Partners
City Therapeutics$99M · 2026-06-08
Andrew Beck
Beacon Biosignals$27M · 2021-11-08
Anthony Philippakis
Beacon Biosignals$97M · 2025-11-13
Arif Nathoo
Beacon Biosignals$27M · 2021-11-08
Axon Partners Group
ONI$75M · 2022-01-20
B Capital
Nest Genomics$8M · 2023-01-10
BECO Capital
Codiak Biosciences$76M · 2017-11-29
Bessemer Venture Partners
Thyme Care$22M · 2021-10-05
BVF Partners L.P.
EQRx$1.8B · 2021
Byers Capital
Octave Bioscience$35M · 2025-09-04
Commodore Capital
Neurogene$200M · 2024-11-04
Defy
Nautilus Biotechnology$76M · 2020
Dolby Family Ventures
Cerevance$20M · 2020-07-21
Dragoneer Investment Group
Formation Bio$156M · 2021-09-30
Duquesne Family Office
C2i Genomics$100M · 2021-04-15
E14 Fund
Volta Labs$20M · 2022-03-18
Euclidean Capital
23andMe$250M · 2017-09-12
Felicis
Formation Bio$156M · 2021-09-30
Fifty Years
Multiply Labs$20M · 2021
Founders Fund
Multiply Labs$20M · 2021
Gaurav Singal
Beacon Biosignals$27M · 2021-11-08
Gobi Partners
C2i Genomics$100M · 2021-04-15
Hercules Capital, Inc.
908 Devices$— · 2019-04-29
Hive Ventures
Vineti$35M · 2020-02-05
Horizons Ventures
Asimov$175M · Unknown date
Iaso Ventures
Beacon Biosignals$97M · 2025-11-13
Illumina Ventures
Volta Labs$20M · 2022-03-18
Indicator Ventures
Beacon Biosignals$97M · 2025-11-13
Innovation Endeavors
Character Biosciences$93M · 2025-03-25
Innoviva
Beacon Biosignals$97M · 2025-11-13
Intermountain Health
Octave Bioscience$35M · 2025-09-04
Jefferson Life Sciences
Character Biosciences$93M · 2025-03-25
Kite, a Gilead Company
Vineti$35M · 2020-02-05
LionBird
Nest Genomics$8M · 2023-01-10
Luma Group
Character Biosciences$93M · 2025-03-25
Lux Capital
Multiply Labs$20M · 2021
Mass General Brigham Ventures
Rome$72M · Unknown date
Maverick Ventures
Volta Labs$20M · 2022-03-18
Mubadala Investment Company
EQRx$1.8B · 2021
Nexus NeuroTech Ventures
Beacon Biosignals$97M · 2025-11-13
NFX
C2i Genomics$100M · 2021-04-15
Novartis
Octave Bioscience$35M · 2025-09-04
Ona Capital
Codiak Biosciences$76M · 2017-11-29
OrbiMed
Nautilus Biotechnology$76M · 2020
Oxford Science Enterprises
ONI$75M · 2022-01-20
Pathfinder
Multiply Labs$20M · 2021
Perceptive Advisors
Earli$— · Unknown date
PSP Investments
Prime Medicine, Inc.$200M · 2021-07-13
Public Sector Pension Investment Board
Prime Medicine, Inc.$— · Unknown date
Razor's Edge Ventures
908 Devices$— · 2019-04-29
Rock Springs Capital
City Therapeutics$99M · 2026-06-08
RTW Investments, LP
Neurogene$200M · 2024-11-04
Samsung Next
Nest Genomics$8M · 2023-01-10
Sands Capital
Earli$— · Unknown date
Silver Lake
C2i Genomics$100M · 2021-04-15
Sofinnova Partners
City Therapeutics$99M · 2026-06-08
Sound Ventures
Formation Bio$156M · 2021-09-30
Spark Capital
Formation Bio$156M · 2021-09-30
Surveyor Capital
Remix Therapeutics$60M · 2024-01-03
Synetro Group
Beacon Biosignals$97M · 2025-11-13
T. Rowe Price
Prime Medicine, Inc.$— · Unknown date
T. Rowe Price Associates
Prime Medicine, Inc.$200M · 2021-07-13
Takeda
Beacon Biosignals$97M · 2025-11-13
Tao Capital Partners
908 Devices$— · 2019-04-29
Threshold Ventures
Vineti$35M · 2020-02-05
Thrive Capital
Formation Bio$156M · 2021-09-30
Town Hall Ventures
Thyme Care$60M · 2023-08-22
UPMC Enterprises
Cerevance$20M · 2020-07-21
Vertex Ventures HC
Sonoma Biotherapeutics$265M · 2021-08-04
Vertical Venture Partners
ONI$75M · 2022-01-20
W.T.T. Investment Ltd.
Remix Therapeutics$60M · 2024-01-03

